Relamorelin
Also known as: BIM-28131, Relamorelin, relamorelin acetate, RM-131, Ulimorelin analog
Source Relamorelin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Relamorelin (RM‑131, BIM‑28131) is a synthetic octapeptide ghrelin receptor agonist developed to accelerate gastric emptying and treat diabetic gastroparesis and other motility disorders. It is administered by injection and has shown efficacy in Phase II/III trials but is not yet approved.
Mechanism of Action
Synthetic ghrelin analog that binds and activates the growth hormone secretagogue receptor (GHSR), stimulating growth hormone release and enhancing gastrointestinal motility.
Routes of Administration
Goals & Uses
- Reduction of nausea and vomitingSymptom ManagementModerate
- Chronic idiopathic gastroparesisGastrointestinal MotilityLow
- Acceleration of gastric emptyingGastrointestinal MotilityModerate
- Post‑operative ileusGastrointestinal MotilityLow
- Chronic constipationGastrointestinal MotilityModerate
- Improvement in postprandial fullness and bloatingSymptom ManagementLow
- Diabetic gastroparesis symptom reliefGastrointestinal MotilityModerate
- Diabetic gastroparesisGastrointestinal MotilityHigh
Contraindications
- Mechanical gastrointestinal obstructionGastrointestinalHigh
- Hypersensitivity to relamorelin or excipientsAllergy/ImmunologyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Known hypersensitivity to relamorelin or excipientsAllergyHigh
- Gastrointestinal perforation or hemorrhageGastrointestinalHigh
Adverse Effects
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Abdominal pain or crampingGastrointestinalUncommon
- Transient hyperglycemiaMetabolic/EndocrineUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Growth hormone elevationEndocrineUncommon
- DiarrheaGastrointestinalCommonLoose or frequent stools
- Abdominal painGastrointestinalUncommonPain or discomfort in the abdomen
Drug Interactions
- Other ghrelin agonists or GH secretagoguesModerate
- CYP450 substratesLow
- OpioidsModerate
- Anticholinergic agentsModerate
- Insulin and antidiabetic medicationsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeAbsolute
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionInvestigationalNo marketing authorization; clinical studies in progress.
- United StatesInvestigationalPhase III trials ongoing; Fast Track for diabetic gastroparesis.
- United KingdomInvestigationalUnder MHRA review for trial use.
Granted Fast Track designation by the FDA for diabetic gastroparesis; not approved for any indication in the US, EU, or UK as of 2026.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Relamorelin?
Relamorelin (RM‑131, BIM‑28131) is a synthetic octapeptide ghrelin receptor agonist developed to accelerate gastric emptying and treat diabetic gastroparesis and other motility disorders. It is administered by injection and has shown efficacy in Phase II/III trials but is not yet approved.
What is Relamorelin used for?
Relamorelin is educationally associated with: Reduction of nausea and vomiting, Chronic idiopathic gastroparesis, Acceleration of gastric emptying, Post‑operative ileus, Chronic constipation, Improvement in postprandial fullness and bloating, Diabetic gastroparesis symptom relief, Diabetic gastroparesis. Educational only — not medical advice.
How is Relamorelin administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Relamorelin?
Reported adverse effects include: Injection site reactions, Headache, Abdominal pain or cramping, Transient hyperglycemia, Nausea, Growth hormone elevation, Diarrhea, Abdominal pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Relamorelin?
Recorded contraindications: Mechanical gastrointestinal obstruction, Hypersensitivity to relamorelin or excipients, Pregnancy, Known hypersensitivity to relamorelin or excipients, Gastrointestinal perforation or hemorrhage. Consult a qualified clinician before use.